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Abstract 
Background: Preeclampsia is a major cause of morbidity and mortality, both maternal and perinatal. The etiology 
and pathophysiology of preeclampsia remain unknown. Research shows the implantation of the placenta in preec-
lampsia occurs due to incomplete angiogenic imbalance as one of the preeclampsia pathogenesis. PlGF is angiogenic 
protein which is synthesized in placenta by mRNA PlGF. When damage occurs, mRNA will be released from cell and 
form cell-free mRNA. This study aims to analyze the differences between the PlGF mRNA expression in severe preec-
lampsia and normal pregnancy as well as to measure the relationship between cell-free mRNA and levels of PlGF with 
the incidence of severe preeclampsia.
Methods: The method used in this study is an observational analytic study with cross-sectional design. Blood sam-
ples were obtained from patients with preeclampsia and normal pregnancies as the controlling factors in accordance 
with inclusion and exclusion criterias. Examination of the PlGF level was measured by ELISA method and mRNA PIGF 
expression was measured by RT-PCR. Physical and laboratory examinations of patients were recorded and collected as 
data. Calculations were done by statistical analysis.
Results: Mean of the cell-free mRNA PlGF expression level in severe preeclampsia is 2.2983 ng/mL within the scale of 
1.96–2.83 ng/mL and deviation standard of 0.1897. Using Pearson Analysis Test, the result shows that there is a posi-
tive correlation between cell-free mRNA expression and PlGF protein level in severe preeclampsia, with r = 0.640 dan 
p < 0.004.
Conclusion: There is no difference between expression of cell-free mRNA PlGF in severe preeclampsia serum and 
normal pregnancy. There is a significant correlation between expression of cell-free mRNA and PlGF protein level in 
severe preeclampsia.
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Background
Hypertension remains a leading cause of maternal mor-
tality and morbidity. Gestational hypertension is defined 
as hypertension disease which occurs in pregnancy, con-
sisting of: (1) gestational hypertension, (2) preeclampsia 
and eclampsia syndrome, (3) chronic hypertension which 
is worsened by preeclampsia, and (4) chronic hyperten-
sion. Preeclampsia and eclampsia syndrome are the high-
est risk among others [1–3]. Preeclampsia and eclampsia 
syndrome are further called as preeclampsia and eclamp-
sia. Diagnose of preeclampsia is clinically established 
if there is an increased blood pressure more than 
140/90 mmHg and proteinuria is more than 300 mg/24 h 
(dipstik +1) with or without edema.
Incomplete placental implantation in preeclampsia 
is caused by angiogenic imbalance as one of pathogenic 
factors. Angiogenic substance, placental growth factor 
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(PlGF) is considered to play its role. PlGF is produced by 
trophoblast which is responsible in placentation and it 
is believed to play its role as angiogenic. Studies showed 
that PlGF has both angiogenic and antiangiogenic prop-
erties depending on pathophysiological conditions [4]. 
The levels of circulatory PlGF increase gradually and 
peak at mid gestation before declining again in unevent-
ful pregnancies. PlGF concentration profile follows a sim-
ilar pattern in women who later developed preeclampsia, 
however with decreased amplitude. Reducing levels of 
PlGF serum in first trimester causes angiogenesis pla-
centa imbalance, which leads to preeclampsia in second 
or third trimester [5, 6].
PlGF concentrations are already significantly reduced 
at the end of the first trimester and remain lower 
throughout pregnancy. Yet, the difference in circula-
tory PlGF between normotensive pregnancies and those 
affected by preeclampsia is the highest within weeks of 
the onset of the clinical symptoms. As with sFlt-1, the 
pre-symptomatic levels of circulatory PlGF is thought to 
associate with the severity or time of onset of preeclamp-
sia [7]. Urinary PlGF is likewise lower in preeclamptic 
patients before and at the time of symptoms [8, 9].
PlGF protein is produced by ribosome involving DNA 
to form polypeptide chain via RNA form. It has been 
reported that there is a circulating fetal mRNA in mater-
nal serum and the role remains unknown. There is one or 
two such cells per millimeter maternal blood in second 
trimester pregnancy. They are composed of trophoblast 
cells, lymphocytes, and nucleated red blood cells (NRBCs). 
NRBCs originate from fetus carrying fetal cytoplasm and 
embryonic hemoglobin. However, maternal erythroid pre-
cursors containing smaller amounts of these hemoglobins 
are also present. Paternal DNA sequencing test showed 
the difference whether blood is derived from fetus or 
maternal, with 50% specificity in chromosome Y [10].
Circulating fetal cells elevate in Down syndrome and 
preeclampsia. It has been reported that chromosome-
Y sequences could be detected by PCR assay to diag-
nose cycle-cell anemia and thalassemia B in fetus [11]. 
Chromosome Y from cell-free fetal DNA (cff-DNA) was 
detected by PCR method in serum of pregnant women 
carrying male fetuses [10, 12]. Source of cff-DNA in 
maternal circulation remains unclear. It has been hypoth-
esized that cff-DNA originates from fetal cell lysis by the 
reaction of maternal immune, cell apoptosis during fetus 
development, trophoblast cell apoptosis and placental 
aging. Cff-DNA disappears few hours after birth [10].
The value of cff-DNA in maternal plasma as an indica-
tor for preeclampsia has first been reported by Lo et al. in a 
small scale study in the plasma of 20 preeclamptic women 
and 20 gestational age matched controls in the third trimes-
ter, where cff-DNA was increased approximately fivefold in 
women with preeclampsia [10]. The same effect in the sec-
ond trimester was investigated by Zhong et al. in 10 preec-
lamptic women and 40 controls [13]. The so far biggest 
study regarding the role of cff-DNA in preeclampsia was 
conducted by Levine et al. with 120 preeclamptic women 
and 120 controls: A two to fivefold increase of cff-DNA 
levels was monitored starting from week 17 until 3 weeks 
before the onset of preeclampsia [14]. As the amount of 
fetal DNA is routinely determined by quantifying Y-chro-
mosome specific sequences, e.g. SRY (sex determining 
region Y) and DYS [15], alternative approaches have been 
performed to overcome this limitation: Increased total 
cff-DNA was observed in women with preeclampsia at 
term [16–18] and before the onset of preeclampsia [18]. 
Approaches to analyze cff-DNA independent from fetal 
sex, using epigenetic differences between maternal and fetal 
DNA have been developed, e.g. the use of the maspin gene, 
which is hypomethylated in fetal tissue [19] or the hyper-
methylated fetal promoter sequence of RASSF1A [20]. 
Although these approaches are promising, only one study 
quantifying cff-DNA with the RASFF1A approach in 10 
women with preeclampsia and 20 controls has been pub-
lished [21]. Cff-DNA has shown some predictive value for 
the prediction of preeclampsia between 20 and 25  weeks 
of gestation, however, higher sensitivities and specificities 
can be obtained by combining several markers as has been 
shown in a nested case–control study for cff-DNA com-
bined with Inhibin A in the second (n = 15 at risk for PE, 
n = 68 controls) and third trimester (n = 34 preeclampsia, 
n = 44 controls) [22]. Currently, several multicenter stud-
ies are being performed to confirm the predictive value of 
cff-DNA to predict and monitor preeclampsia in combina-
tion with other potential markers, e.g. P-selectin, PAPP-A, 
PP-13, sFlt-1, sEng, PlGF).
The study of finding the correlation between expression 
of cff-mRNA and levels of protein in maternal serum is 
rarely done. The previous studies showed that there is a 
correlation between cff-mRNA specific gene expression 
with protein expression in preeclamptic patients, which 
refers to corticotropin releasing hormone (CRH) gene. 
This study aims to know the difference between cell-free 
mRNA PlGF expression in preeclamptic patients and the 
correlation with PlGF protein level. It is expected to be 
one of foundations to understand preeclampsia and fetal-
maternal genetic material transfers in placenta.
Result
Characteristic data, systolic and diastolic blood pressure, 
measurement of proteinuria, and blood to be measured 
for PlGF and cff-mRNA PlGF in Prodia laboratory Band-
ung were collected from both study groups. Characteris-
tics of age, parity, and gestational age were compared for 
homogeneity.
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As shown in Table 1, there is no significant difference 
(p > 0.05) in age, parity and gestational age between the 
two groups. Characteristics of subjects are therefore 
homogenous. Data distribution of PlGF level and cff-
mRNA PlGF expression obtained is further examined by 
Shapiro–Wilk normality test. Results showed that PlGF 
level and cell-free mRNA PlGF expression are not nor-
mally distributed (p < 0.05). Result of normal distribution 
obtained was done by conversion analysis to log.
Table  2 shows comparison cff-mRNA PlGF expres-
sion level between severe preeclampsia and nor-
mal pregnancy. There is no change between the two 
groups (p = 0.744). PlGF protein level in preeclampsia 
is significantly lower than that in normal pregnancy 
(p < 0.001).
There is a correlation between cff-mRNA PlGF expres-
sion and PlGF protein level in severe preeclampsia, as 
shown in Figure 1. Expression of cff-mRNA PlGF is sig-
nificantly correlated to the levels of PlGF protein which 
is performed by log calculation. It leads to the theory that 
mRNA which is located outside cytoplasm is able to be 
expressed into a protein.
Discussion
Characterization of research subjects
This research has 37 subjects involving 18 subjects with 
severe preeclampsia and 19 subjects with normal preg-
nancy as controls. Characterization of the subjects in 
those groups has no significant difference in parity and 
gestational age.
Group matching was done between severe preeclamp-
sia and controls. Characterization data is homogenous 
(p  >  0.05), as shown in Table  1. There is no significant 
difference between the two groups which is performed 
by Chi square test with confidence level of 95%. The 
characteristics of mothers with p  >  0.05 in both groups 
respectively are; age, p = 0.831; parity, p = 0.195; and ges-
tational age, p = 0.221. It is rare to find such characteris-
tics in cohort studies, especially in finding the predictor 
of the number of parity and previous obstetric history. 
Incident of preeclampsia is usually higher in primi or nuli 
gravida [2, 23]. It is associated to the theory that the first 
time exposure of villi khorialis is one of the predisposing 
factors in preeclampsia. Consecutive sampling that may 
Table 1 Characterization of subjects
* p value for age and parity was analyzed with Chi Square test.
** p value for gestational age was analyzed with Fisher’s exact test.





1. Age (years old)
 <20 4 1 15 0.303*
 21–34 11 15 16
 >35 3 3 6
 x (SD) 27.4 (7.1) 27.0 (5.3)
 Range 17–40 20–36
2. Parity
 Nulipara 7 6 13 0.195*
 Para 11 13 24
3. Gestational age (week)
 37 8 10 18 0.221**
 38 6 2 8
 ≥39 4 7 11
(±SD) 37.1 (2.6) 37.02 (4.3)
Range 32–41 24–42
Table 2 Comparison of cell-free mRNA PlGF expression 
between PlGF protein level in severe preeclampsia with 
normal pregnancy
Variable Group t test P value
PEB (n = 18) Normal (n = 19)
Log PlGF
 x (SD) 1.7418 (0.5015) 2.4551 (0.4449) 4.582 <0.001
 Range 1–3.13 1.73–3.06
 x p (95/
ci)
55.18 (31.07–97.99) 285.17 (174.02–
467.20)
Log mRNA PlGF
 x (SD) 2.2983 (0.1897) 2.325 (0.2906) 0.329 0.744
 Range 1.96–2.83 1.96–3.33
























R Sq Linear = 0.409
Figure 1 There is correlation between cell-free mRNA PlGF expres-
sion and PlGF protein level in severe preeclampsia. By using log 
calculation, it showed there is significant correlation between cell-free 
mRNA PlGF expression and PlGF protein level.
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cause differences in parity effect is not significant in this 
research.
PlGF protein level obtained was analyzed by Shapiro–
Wilks test as shown in Table  2. The difference between 
the results is clearly caused by the small amount of 
samples.
Comparison of cell‑free mRNA expression in severe 
preeclampsia and in normal pregnancy
Table  2 shows that there is no difference between cff-
mRNA PlGF expression in preeclampsia and normal 
pregnancy (p < 0.744). However, PlGF protein level is sig-
nificantly lower in severe preeclampsia than PlGF level in 
normal pregnancy.
Expression of cff-mRNA PlGF has never been investi-
gated. It is assumed that cff-mRNA PlGF is responsible 
for PlGF synthesis circulating in maternal circulation. Its 
roles are similar to other mRNA proteins. Synthesis by 
mRNA results in certain benefit in angiogenesis in preg-
nant women. Expression of cff-mRNA PlGF is therefore 
expected to be comparable with levels of PlGF which is 
lower in severe preeclampsia than in normal pregnancy. 
Surprisingly, there is no difference between cff-mRNA 
PlGF expression in preeclampsia and normal pregnancy 
as shown in Table  2. Different study designs should be 
used in checking the validity of the study.
Table  2 shows that there is a significant difference of 
PlGF level in severe preeclampsia than that of normal 
pregnancy (p  <  0.001). It has been analyzed that PlGF 
serum level in preeclampsia is lower than in normal preg-
nancy. This is related to the previous studies of reduced 
PlGF due to hipoxia placenta in preeclamptic patients 
[23, 24].
The role of PlGF is not fully understood. It has been 
reported that PlGF binds with sFlt-1. They play role as 
angiogenic. However, studies show that PlGF has both 
angiogenic and antiangiogenic properties depending 
on pathophysiological conditions. PlGF level elevates in 
midtrimester in normal pregnancy and it is associated 
with sFlt-1 level. It is known to be based on the com-
parison the PlGF level. The role of PlGF level is pre-
dominant in the development of the placenta. PlGF is 
produced in endothelial, trophoblast, monosite and eri-
troid cells. Hypoxia induces degradation of Glial Cell 
Missing 1 (GCM1), PIGF transcription factor in troph-
oblast cells, and PlGF production. Metal-responsive 
transcription factor (MTF-1) is thought to play role in 
PlGF synthesis in trophoblast cells. Moreover, MTF-1 
reduces when hypoxia is present. However, VEGF and 
sVEGFR-1 syntheses elevate in hypoxia regulated by 
hipoxia inducible factor (HIF-1) in placenta. Thus, it 
leads to overproduction of VEGF and sVEGFR-1 in 
preeclampsia [25].
PlGF synthesis is possibly generated by VEGF in 
endothelial cell through mechanism which is associated 
with protein kinase C and mitogen-activated protein 
kinase (MEK). PlGF synthesis will reduce due to placen-
tal hypoxia and elevated sVEGF-1. Angiogenic levels are 
extremely low in circulatory which leads to endothelial 
dysfunction and indicates preeclampsia [25, 26].
Correlation between cell‑free mRNA expression and PlGF 
Protein level in severe preeclampsia
The cell-free mRNA PlGF expression level is posi-
tively correlated with PlGF protein level in PEB group 
(r =  0.640 dan p  <  0.004), as shown in Figure 1. Newly 
formed mRNA plays role as matrix for protein synthesis 
(mRNA).
There are only few gene fragments containing genetic 
code in nucleic cells. Mature RNA is released from 
nucleus and it binds to ribosome in cytoplasm. RNA is 
translated in order to match the amino acids sequence 
(protein) [27, 28]. Placental RNA cells are released from 
cytoplasm cell. Then, they form a cell-free mRNA in the 
damage cell such as apoptosis.
Nucleic cells transfer in uteroplacental circulation is 
reported to undergo in two directions, from mother to 
fetus back and forth. The transfer causes microchimer-
ism and triggers autoimmune disease in pregnancy. The 
transfer also occurs in DNA. It has been reported that cff 
maternal DNA is present in fetus umbilical vein blood, 
and its number is lower than that in maternal circula-
tion. PIGF protein synthesis in placenta is assumed to 
be affected by cff-mRNA PlGF in maternal circulation as 
well.
Conclusion
There is no difference between expression of cell-free 
mRNA PlGF in severe preeclampsia serum and nor-
mal pregnancy. However, levels of PlGF serum in severe 
preeclampsia is significantly lower than in normal preg-
nancy. There is a significant correlation between expres-
sion of cell-free mRNA and PlGF protein level in severe 
preeclampsia.
Methods
This is a cross-sectional analytic observational research. 
Data are taken once in two groups, both in preeclampsia 
and in normal pregnancy. Test of PlGF level and cell-free 
mRNA PlGF serum expression have been done to those 
two groups and blood pressure. Edema and proteinuria 
test have also been done to confirm severe preeclampsia 
diagnose.
Patients with preeclampsia (18 samples), and nor-
mal pregnancies as controls (19 samples) were managed 
according to the guidelines therapy of Obstetric and 
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Gynecology Faculty of Medicine Padjadjaran Univer-
sity Hasan Sadikin Hospital (FKUP/RSHS), Bandung, 
through some tests: (1) anamnesis; name, age, address, 
parity, first day of the last period, gestational age, previ-
ous hypertension history, and current pregnancy disease. 
(2) blood pressure was measured by using sphygmoma-
nometer to the patients who were treated by lying on 
their left side for 15 min. (3) 6 ml blood sample was taken 
from peripheral blood before birth, centrifuge at 1,600g 
10’ 4  °C. Blood sample was withdrawn and then kept in 
−20  °C temperature. (4) RNA total was extracted from 
1.6  mL plasma, homogenized with 2  mL reagent Tri-
zol LS (Invitrogen) and 0.4 chloroform. Suspension was 
centrifuged at 12,000g 15’ 4 °C, aqueous was removed to 
another tube. Suspension has been added by 1 volume 
700  mL/L ethanol, 1 volume aqueous, then added to 
QIAamp MinElute Virus Column (Qiagen) and processed 
by manufacture recommend. RNA total was eluted by 
20 µL Rnase-free water was directly transcribed. Exami-
nation of cff mRNA levels was performed by QIAamp 
MinElute Virus column to separate DNA from RNA, Tag-
Man PCR analysis was performed to determine protein. 
Level of PlGF serum was performed by high sensitivity 
indirect sandwich enzyme-linked immunosorbent assay 
(ELISA).
Data analysis was begun by performing normality 
test. Categorical data were analyzed with Chi square or 
Fisher’s exact test when the expected value was less than 
5. Normally-distributed data were compared with t test, 
while not-normally-distributed ones were analyzed with 
Mann–Whitney test. Ratio of proteins was analyzed 
with Spearman’s rank correlation test. Data analysis was 
performed with Statistical Package for The Social Sci-
ences software (SPSS) or Windows version 15.0, with 
85% confidence interval and p value of <0.05. Written 
consent were obtained from all participants. The ethical 
review boards of the Health Research Ethics Commit-
tee, the Faculty of Medicine, Padjadjaran University and 
Dr. Hasan Sadikin Hospital, Indonesia approved this 
study.
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